2. Search Result
Search Result
Results for "

Olaparib

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10162
    Olaparib
    200+ Cited Publications

    AZD2281; KU0059436

    		 PARP Autophagy Mitophagy Cancer
    Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .
    Olaparib
  • HY-10162S
    Olaparib-d5

    AZD2281-d5; KU0059436-d5

    		 PARP Autophagy Mitophagy Cancer
    Olaparib-d5 is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
    Olaparib-d5
  • HY-10162R
    Olaparib (Standard)

    		PARP Autophagy Mitophagy Cancer
    Olaparib (Standard) is the analytical standard of Olaparib. This product is intended for research and analytical applications. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .
    Olaparib (Standard)
  • HY-10162S1
    Olaparib-d8

    AZD2281-d8; KU0059436-d8

    		 PARP Autophagy Mitophagy Cancer
    Olaparib-d8 is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].
    Olaparib-d8
  • HY-10162S3
    Olaparib-d4-1

    AZD2281-d4-1; KU0059436-d4-1

    		 Isotope-Labeled Compounds PARP Autophagy Mitophagy Cancer
    Olaparib-d4-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].
    Olaparib-d4-1
  • HY-120115
    PARPi-FL

    Olaparib-bodipy FL

    		 PARP Fluorescent Dye Cancer
    PARPi-FL is a small molecule and fluorescent inhibitor of PARP1. PARPi-FL is a highly selective probe and can be used as an imaging agent to detect glioblastomas in vivo. (Excitation/Emission max 507/525 nm) .
    PARPi-FL
  • HY-75706
    N-Descyclopropanecarbaldehyde Olaparib

    		E3 Ligase Ligand-Linker Conjugates PARP Cancer
    N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based ligand for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
    N-Descyclopropanecarbaldehyde Olaparib
  • HY-W869159S
    2-Fluorobenzyl olaparib-d4

    		Isotope-Labeled Compounds Others
    2-Fluorobenzyl olaparib-d4 is a deuterium labeled compound.
    2-Fluorobenzyl olaparib-d4
  • HY-161606
    PARP-1/2/7-IN-1

    		PARP Cancer
    PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC50 of ＜ 10 nM .
    PARP-1/2/7-IN-1
  • HY-161607
    PARP7-IN-21

    		PARP Cancer
    PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC50 of ＜ 10 nM .
    PARP7-IN-21
  • HY-161868
    DLC-50

    		PARP HDAC Apoptosis Cancer
    DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase .
    DLC-50
  • HY-163743
    SIC-19

    		Salt-inducible Kinase (SIK) Cancer
    SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .
    SIC-19
  • HY-149001
    PARP1-IN-9

    		PARP Cancer
    PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC50 of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .
    PARP1-IN-9
  • HY-162633
    USP1-IN-9

    		Deubiquitinase Cancer
    USP1-IN-9 (Compound 1m) is reversible and noncompetitive ubiquitin-specific proteases (USP1) inhibitors with an IC50 of 8.8 nM, which is designed and synthesized to pyrido[2,3-d]pyrimidin-7(8H)-one derivative based on the disclosed structure of ML323(HY-17543) and KSQ-4279(HY-145471). USP1-IN-9 displays excellent USP1/UAF inhibition and exhibits strong antiproliferation effect in breast cancer cells. USP1-IN-9 can generate enhanced cell killing with PARP inhibitor olaparib(HY-10162) in olaparib-resistant MDA-MB-436/OP cells, which is promising for research in the field of cancer .
    USP1-IN-9
  • HY-162859
    AB25583

    		Others Cancer
    AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC50 value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .
    AB25583
  • HY-162896
    And1 degrader 1

    		Others Cancer
    And1 degrader 1 (Compound A15) is a degrader of the acidic nucleoplasmic DNA-binding protein 1 (And1), which can significantly induce the degradation of And1 in NSCLC cells. And1 degrader 1 (5 μM) combined with Olaparib (HY-10162) (1 μM) effectively inhibits the proliferation of A549 and H460 cells. And1 degrader 1 can be used in cancer research .
    And1 degrader 1
  • HY-139039
    BSJ-4-116

    		PROTACs CDK Cancer
    BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib (HY-10162) .
    BSJ-4-116
  • HY-155993
    YCH1899

    		PARP Cancer
    YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .
    YCH1899
  • HY-115552
    Simmiparib

    		PARP Cancer
    Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC50 values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib (HY-10162). Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis. Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts .
    Simmiparib
  • HY-151624
    PARP-2-IN-2

    		PARP Apoptosis Cancer
    PARP-2-IN-2 (compound 27) is a PARP‑2 inhibitor with an IC50 value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .
    PARP-2-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: